KR20160131998A - 종양 백신 - Google Patents

종양 백신 Download PDF

Info

Publication number
KR20160131998A
KR20160131998A KR1020167009027A KR20167009027A KR20160131998A KR 20160131998 A KR20160131998 A KR 20160131998A KR 1020167009027 A KR1020167009027 A KR 1020167009027A KR 20167009027 A KR20167009027 A KR 20167009027A KR 20160131998 A KR20160131998 A KR 20160131998A
Authority
KR
South Korea
Prior art keywords
peptide
leu
seq
arg
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167009027A
Other languages
English (en)
Korean (ko)
Inventor
버트랜드 빅터 길버트 조지
칼튼 브래들리 브라운
Original Assignee
알티뮨 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알티뮨 유케이 리미티드 filed Critical 알티뮨 유케이 리미티드
Publication of KR20160131998A publication Critical patent/KR20160131998A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167009027A 2013-09-06 2014-09-04 종양 백신 Ceased KR20160131998A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1315946.2 2013-09-06
GBGB1315946.2A GB201315946D0 (en) 2013-09-06 2013-09-06 Oncology vaccine
PCT/GB2014/052675 WO2015033140A1 (en) 2013-09-06 2014-09-04 Oncology vaccine

Publications (1)

Publication Number Publication Date
KR20160131998A true KR20160131998A (ko) 2016-11-16

Family

ID=49486881

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167009027A Ceased KR20160131998A (ko) 2013-09-06 2014-09-04 종양 백신

Country Status (9)

Country Link
US (1) US20160199469A1 (enExample)
EP (1) EP3041493A1 (enExample)
JP (1) JP2016530290A (enExample)
KR (1) KR20160131998A (enExample)
AU (1) AU2014316791A1 (enExample)
CA (1) CA2922467A1 (enExample)
GB (1) GB201315946D0 (enExample)
MX (1) MX2016002937A (enExample)
WO (1) WO2015033140A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190112271A (ko) * 2017-01-27 2019-10-04 이매틱스 바이오테크놀로지스 게엠베하 난소암 및 다른 암에 대한 면역요법에 사용을 위한 신규 펩티드 및 펩티드의 조합

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
GB201520539D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017096247A1 (en) 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
PT3463436T (pt) 2016-06-02 2023-12-28 Ultimovacs As Uma vacina em combinação com um inibidor de ponto de verificação imune para utilização no tratamento do cancro
BR112019018307A2 (pt) 2017-03-03 2020-03-31 Treos Bio Zrt Plataforma para identificação de peptídeos imunogênicos baseada em população
JP2020515629A (ja) 2017-04-04 2020-05-28 アヴィディア テクノロジーズ, インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
JP2021520414A (ja) * 2018-04-04 2021-08-19 アルティミューン インコーポレーティッド T細胞を誘発するワクチン組成物の組合せ及びその使用
ES2935702T3 (es) * 2018-04-11 2023-03-09 Enterome S A Péptidos antigénicos para la prevención y el tratamiento del cáncer
US20210340201A1 (en) * 2018-08-22 2021-11-04 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
KR20230009426A (ko) * 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles
WO2025227519A1 (zh) * 2024-04-29 2025-11-06 北京臻知医学科技有限责任公司 一种肿瘤疫苗及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511266A (ja) * 1998-04-15 2002-04-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 腫瘍関連核酸及びその使用
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030224036A1 (en) * 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
WO2001055393A2 (en) * 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
GB0609121D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
DK2280721T3 (da) * 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
US20120328660A1 (en) * 2011-06-03 2012-12-27 Tsuji Takemasa Immunogenic compositions useful in provoking an integrated response to tumor antigens

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190112271A (ko) * 2017-01-27 2019-10-04 이매틱스 바이오테크놀로지스 게엠베하 난소암 및 다른 암에 대한 면역요법에 사용을 위한 신규 펩티드 및 펩티드의 조합

Also Published As

Publication number Publication date
US20160199469A1 (en) 2016-07-14
JP2016530290A (ja) 2016-09-29
EP3041493A1 (en) 2016-07-13
CA2922467A1 (en) 2015-03-12
WO2015033140A1 (en) 2015-03-12
MX2016002937A (es) 2016-07-07
GB201315946D0 (en) 2013-10-23
AU2014316791A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
US20160199469A1 (en) Oncology vaccine
KR101216655B1 (ko) Bcl-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도
US20240092843A1 (en) Peptides and methods for the treatment of diabetes
US8663646B2 (en) P53 peptide vaccine
EP2800762B1 (en) Native and agonist ctl epitopes of the muc1 tumor antigen
TW201406390A (zh) 癌疫苗組合物
US9555086B2 (en) Compositions and methods for inducing an immune response
HUE030000T2 (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
CN103547283A (zh) 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法
US20230105457A1 (en) Immunogenic Compounds For Treatment Of Adrenal Cancer
WO2018032501A1 (zh) 一种新的肿瘤特异性多肽及其应用
KR101810840B1 (ko) 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
DK3069138T3 (en) CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
US10286050B2 (en) Multi-epitope TARP peptide vaccine and uses thereof
US12472247B2 (en) Immune adjuvant comprising hepatitis B virus-derived polypeptide
WO2013175258A1 (en) Novel melanoma antigen peptide and uses thereof
EP4472659A1 (en) Co-vaccination with cd4 and cd8 antigens
WO2023004307A1 (en) T cell epitopes and related compositions useful in the prevention and treatment of respiratory syncytial virus infection
HK1190757A (en) Methods and compositions for inducing an immune response to egfrviii

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160405

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190904

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201223

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210303

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201223

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I